GMNN and prostate cancer: Our integrative analysis combined a diverse panel of protein markers known to predict recurrence after prostate cancer radiotherapy and identified that markers of proliferation (Ki67 or Geminin) as well as PTEN loss predicted recurrence independently of prognostic factors currently used in the clinic.